Boosting the endocannabinoid system before the treatment of anxiety symptoms
- Conditions
- anxiety disorders and PTSD10002861
- Registration Number
- NL-OMON52231
- Lead Sponsor
- niversitair Medisch Centrum Utrecht
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 82
• Dutch uniformed personnel (i.e. (former) police officers, firefighters,
ambulance paramedics, military personnel or veterans
• Age between 18-65
• Waiting for therapy for the treatment of a trauma and stressor-related and/or
an anxiety disorder
• Severe co-morbidity (severe major depressive or bipolar disorder and/or
psychosis)
• Alcohol and/or drug dependence
• Inability to adequately read or speak Dutch
• (a history of) epilepsy or brain damage, cardiac, renal or liver abnormalities
• (a history of) allergies to medication (adverse reactions or rash)
• Individuals taking certain medications known to have potential interactions
with CBD (i.e., steroids, HMG-CoA reductase inhibitors, calcium channel
blockers, antihistamines, antivirals, immune modulators, benzodiazepines,
anti-arrhythmic, antibiotics, anesthetics, antipsychotics, antidepressants,
anti-epileptics, beta blockers, proton pump inhibitors, NSAIDs, angiotensin II
blockers, oral hypoglycemic agents, and sulfonylureas)
• Used cannabis, synthetic cannabinoid, cannabinoid analogue, or any CBD or
THC-containing product within 30 days of eligibility screening.
• Individuals that had been diagnosed with intestinal, liver, or renal diseases
that would affect absorption or clearance of CBD
• For women: pregnant, a wish to become pregnant, or nursing
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method